VaxTecBio has several products in preclinical studies and Research and Development. We are working vigorously with its partner to bring them into clinic.
Monovalent SAR-CoV-2 self priming and boosting vaccine for SARS-CoV-2 infection and is in preclinical studies. Nanoparticles of less than 125 nm sizes having been strategically assembled keeping three dimensional structure of antigens intact can illicit an immunogenic response in mice.
Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as Bacillus anthracis. Bivalent vaccine for Anthrax. outer surface of the nanoparticle is synthesized to mimic the surface of Bacillus anthracis and outer surface has stabilized antigen PA. Dual antigen vaccine showed 4 fold increase in antibody production than in single antigen vaccine for PA. Animal data available.
Lyme disease is the most common vector-borne disease in the Northern hemisphere.. Recent studies estimate approximately 476,000 people annually in the United States with the disease. Multivalent vaccine for Lyme disease and is in preclinical studies. Outer surface protein A (OspA) and Complement regulator acquiring surface protein 2 (CspZ) are principal antigens included in the nanoparticles.
Dengue is the world’s most prevalent and important arboviral disease. More than 50% of the world’s population lives at daily risk of infection and it is estimated more than 95 million people a year seek medical care following infection. We have developed a Quadrivalent vaccine for Dengue and is in laboratory studies. Vaccine consisting of chimeras made up of structural pre-membrane (prM) and envelope (E) genes of the four DENV types presented statigically in a nanoparticle.
West Nile virus (WNV), an emerging mosquito-borne and zoonotic flavivirus, continues to spread worldwide and represents a major problem for human and veterinary medicine. vaccine for West Nile Virus is in planning stage.
Novel vaccine for Cancer based on autologous dendritic cells is in planning stage.